# Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

> **NCT03294798** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tianjin SinoBiotech Ltd.** · enrollment: 11 (actual)

## Conditions studied

- Hepatitis B Virus

## Interventions

- **BIOLOGICAL:** Human Serum Albumin/interferon alpha2b fusion protein
- **BIOLOGICAL:** Pegasys

## Key facts

- **NCT ID:** NCT03294798
- **Lead sponsor:** Tianjin SinoBiotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-13
- **Primary completion:** 2019-03-15
- **Final completion:** 2021-03-15
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03294798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03294798, "Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03294798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*